This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 50/3/481    most recent HYPERTENSIONAHA.107.088534v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Costello-Boerrigter, L. C. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Costello-Boerrigter, L. C. Articles by Burnett, J. C., Jr Related Collections Cardio-renal physiology/pathophysiology Structure Animal models of human disease Related Article

(Hypertension. 2007;50:481.)
© 2007 American Heart Association, Inc.

Original Articles

Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction

Lisa C. Costello-Boerrigter; Guido Boerrigter; Gail J. Harty; Alessandro Cataliotti; Margaret M. Redfield; John C. Burnett, Jr

From the Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minn.

Correspondence to Lisa C. Costello-Boerrigter, Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905. E-mail Costello.Lisa{at}mayo.edu

Unlike healthy subjects, overt congestive heart failure cannot "escape" the sodium- and water-retaining actions of mineralocorticoid excess. It is undefined whether escape occurs in asymptomatic left ventricular dysfunction (ALVD), which is characterized by preserved sodium homeostasis, natriuretic peptide activation, and normal circulating aldosterone. We hypothesized that, in ALVD, mineralocorticoid excess with exogenous deoxycorticosterone acetate (DOCA) would overwhelm renal compensatory mechanisms, resulting in sodium and water retention, and promote renal and cardiac collagen deposition. ALVD was induced in 2 groups (N=5 each) of dogs by tachypacing at 180 bpm. Urine was collected daily and blood drawn at baseline and days 2, 5, 8, and 11. One group served as control (ALVD), and the other received DOCA (ALVD+DOCA) starting at day 2 of pacing. Urine flow and sodium excretion were unchanged in the ALVD group. In ALVD+DOCA, urine flow and sodium excretion decreased on the first 2 days DOCA was given but normalized starting day 4. Urine flow and urinary cGMP excretion increased in ALVD+DOCA after DOCA escape. Plasma atrial natriuretic peptide, B-type natriuretic peptide, and cGMP increased equally in both groups. There were no differences in cardiorenal and hemodynamic parameters in an acute study on day 11. Although renal collagen area fraction was similar, left ventricular collagen area fraction in ALVD+DOCA was significantly higher than in ALVD (3.3±0.4% versus 2.0±0.2%; P=0.012). We conclude that ALVD can escape the sodium- and water-retaining effects of mineralocorticoid excess. Despite renal escape, increased left ventricular collagen deposition suggests that the heart but not the kidney failed to escape the tissue effects of DOCA.

Key Words: basic science • experimental models • extracellular matrix • heart failure • kidney physiology/pathophysiology • mineralocorticoids

Related Article:

Promise of Mineralocorticoid Receptor Blockade in Asymptomatic Left Ventricular Dysfunction

Bertram Pitt
Hypertension 2007 50: 461-462. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				J. Yang and M. J Young The mineralocorticoid receptor and its coregulators J. Mol. Endocrinol., August 1, 2009; 43(2): 53 - 64. [Abstract] [Full Text] [PDF]

				B. P. Shapiro, T. E. Owan, S. Mohammed, M. Kruger, W. A. Linke, J. C. Burnett Jr, and M. M. Redfield Mineralocorticoid Signaling in Transition to Heart Failure With Normal Ejection Fraction Hypertension, February 1, 2008; 51(2): 289 - 295. [Abstract] [Full Text] [PDF]

				B. Pitt Promise of Mineralocorticoid Receptor Blockade in Asymptomatic Left Ventricular Dysfunction Hypertension, September 1, 2007; 50(3): 461 - 462. [Full Text] [PDF]